Despite the analysts’ downbeat assessment, Oliver Sartor, M.D., Director of Radiopharmaceutical Trials and Professor of ...
Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...
BAMF Health in Grand Rapids offers the Pluvicto treatment. It targets only prostate cancer cells with radiation.
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case ...
The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi or Janssen’s Zytiga for mPRPC.
Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer.
The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding ...
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration ...
Bayer is targeting a broader use of Nubeqa in metastatic hormone-sensitive prostate (mHSPC) cancer with a combination free of ...
(ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback